Opioid Rotation in Advanced Kidney Disease
68-year-old man with metastatic prostate cancer and chronic kidney disease stage 4 (eGFR 26 mL/min/1.73 m²) is admitted with worsening bone pain. He takes morphine sulfate extended-release 60 mg every 12 hours plus oxycodone 10 mg every 6 hours as needed, averaging 170 mg oral morphine equivalents daily. Over the past week he has developed diffuse myoclonus, nocturnal confusion, and allodynia over the thighs; his pain is now 8/10 despite the regimen. He denies diarrhea, and pupils are 3 mm. Labs: sodium 134, calcium 9.1, creatinine 3.1, albumin 3.0. QTc is 468 ms. He is anxious and requests 'something stronger.'
1. What is the most likely explanation for the myoclonus, confusion, allodynia, and poor analgesia, and what should be done immediately?
Read the worked answer
The picture is most consistent with opioid-induced neurotoxicity from accumulation of morphine-3-glucuronide and morphine-6-glucuronide in stage 4 CKD, not simply uncontrolled cancer pain. M3G has no analgesic effect but produces myoclonus, hyperalgesia/allodynia, and agitation; M6G is renally cleared and can cause sedation and respiratory depression. The normal pupils, absence of diarrhea, and QTc of 468 ms do not fit pure opioid withdrawal; calcium of 9.1 mg/dL makes hypercalcemia less likely, though infection, brain metastases, and dehydration still need screening. Immediate steps: stop morphine and oxycodone, obtain a medication review, check a bladder scan, and treat reversible causes. Do not escalate the morphine dose; that would worsen neurotoxicity. Start a low-dose opioid from a different class-fentanyl is preferred because it has no renally cleared active metabolites-using small IV boluses or a PCA with careful titration. Add scheduled acetaminophen and consider a short course of dexamethasone for bone pain. Clonazepam may reduce myoclonus but can worsen delirium, so use cautiously. Involve palliative care and monitor sedation, respiratory rate, and mental status.
2. If you rotate to hydromorphone instead of fentanyl, show how you would estimate the starting dose and justify the reduction.
Read the worked answer
I would not apply a single equianalgesic ratio without adjustment. His oral morphine equivalent is about 170 mg/day. Using an oral morphine-to-oral hydromorphone ratio of roughly 5:1, the calculated hydromorphone dose is about 34 mg/day. Because of incomplete cross-tolerance, age, and renal impairment, I would reduce this by at least 50%, and in this setting probably 50–75%, giving roughly 8–17 mg/day. A practical starting regimen is hydromorphone 2 mg orally every 6 hours (8 mg/day) with 1 mg every 2 hours as needed, reassessing every 24 hours. If pain remains severe, I would titrate upward rather than start at the calculated dose. Hydromorphone also has renally cleared metabolites (hydromorphone-3-glucuronide), so it is safer than morphine but not completely risk-free; fentanyl remains the cleaner choice in eGFR 26. I would avoid methadone here because of QTc 468 ms and the complexity of conversion. The key judgment is that the calculated equianalgesic dose is a ceiling for starting, not a target.
3. What monitoring and safety measures would you put in place for the next 48 hours?
Read the worked answer
Monitor pain and sedation every 1–2 hours initially, with respiratory rate, oxygen saturation, and end-tidal CO2 if available. Watch for return of myoclonus, worsening confusion, or new allodynia, which would suggest the new opioid is also accumulating. Check electrolytes, renal function, calcium, and urine output daily; assess for constipation and urinary retention. Avoid NSAIDs because of CKD, and adjust gabapentinoids to renal function if used. Have naloxone available, but do not use it routinely; if respiratory depression occurs, titrate small doses and support ventilation. Document the rationale for the rotation and the incomplete cross-tolerance reduction. Include the family in goals-of-care discussions and clarify that the aim is comfort and function, not a specific pain score. A palliative care pharmacist can help with the conversion and monitoring plan.